Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

Van Cutsem, Eric; Joulain, Florence; Hoff, Paulo M.; Mitchell, Edith; Ruff, Paul; Lakomý, Radek; Prausová, Jana; Moiseyenko, Vladimir M.; van Hazel, Guy; Cunningham, David; Arnold, Dirk; Schmoll, Hans-Joachim; ten Tije, Albert J.; McKendrick, Joseph; Kröning, Hendrik; Humblet, Yves; Grávalos, Cristina; Le-Guennec, Solenn; Andria, Michael; Dochy, Emmanuelle; Vishwanath, Raghu L.; Macarulla, Teresa; Tabernero, Josep

期刊名称Targeted Oncology
作者Van Cutsem, Eric; Joulain, Florence; Hoff, Paulo M.; Mitchell, Edith; Ruff, Paul; Lakomý, Radek; Prausová, Jana; Moiseyenko, Vladimir M.; van Hazel, Guy; Cunningham, David; Arnold, Dirk; Schmoll, Hans-Joachim; ten Tije, Albert J.; McKendrick, Joseph; Kröning, Hendrik; Humblet, Yves; Grávalos, Cristina; Le-Guennec, Solenn; Andria, Michael; Dochy, Emmanuelle; Vishwanath, Raghu L.; Macarulla, Teresa; Tabernero, Josep
印刷ISSN1776-2596
电子ISSN1776-260X
文件大小3295.65KB
发表时间2015-12-26
DOI10.1007/s11523-015-0402-9

发现好书期刊，享受阅读乐趣

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy